Yooseob Shin

Yooseob Shin


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2016 in Experimental & Molecular Medicine
Verified
Journal Article
Open access
PDF file
JLJing-Nan Liu
Jing-Nan Liu
DSDong-Hyeon Suh
Dong-Hyeon Suh
HTHoang Kim Tu Trinh
Hoang Kim Tu Trinh
YCYong-Joon Chwae
Yong-Joon Chwae
HPHae-Sim Park
Hae-Sim Park
YSYooseob Shin
Yooseob Shin
Autophagy has been investigated for its involvement in inflammatory diseases, but its role in asthma has been little studied. This study aimed to explore the possible role of autophagy and its therapeutic potential in severe allergic asthma. BALB/c mice were sensitized with ovalbumin (OVA) on days 0 and 14, followed by primary OVA challenge on days 28–30. The mice received a secondary 1 or 2% OVA challenge on days 44–46. After the final OVA challenge, the mice were assessed for airway responsiveness (AHR), cell composition and cytokine levels in bronchoalveolar lavage fluid (BALF). LC3 expression in lung tissue was measured by western blot and immunofluorescence staining. Autophagosomes were detected by electron microscopy. 3-Methyladenine (3-MA) treatment and Atg5 knockdown were applied to investigate the potential role of autophagy in allergic asthma mice. AHR, inflammation in BALF and LC3 expression in lung tissue were significantly increased in the 2% OVA-challenged mice compared with the 1% OVA-challenged mice (P<0.05). In addition, eosinophils showed prominent formation of autophagosomes and increased LC3 expression compared with other inflammatory cells in BALF and lung tissue. After autophagy was inhibited by 3-MA and Atg5 shRNA treatment, AHR, eosinophilia, interleukin (IL)-5 levels in BALF and histological inflammatory findings were much improved. Finally, treatment with an anti-IL-5 antibody considerably reduced LC3 II expression in lung homogenates. Our findings suggest that autophagy is closely correlated with the severity of asthma through eosinophilic inflammation, and its modulation may provide novel therapeutic approaches for severe allergic asthma.

1 March 2013 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
YYY Ye
Y Ye
HJH Jin
H Jin
EHE Hwang
E Hwang
YNY Nam
Y Nam
JKJ Kim
J Kim
HPHae-Sim Park
Hae-Sim Park
A systemic pro-inflammatory and pro-coagulating state occurs in subjects who have both chronic urtic...

1 February 2014 in Current Opinion in Allergy and Clinical Immunology
Verified
Journal Article
Closed access
MKMi-Ae Kim
Mi-Ae Kim
YSYooseob Shin
Yooseob Shin
LPLe Duy Pham
Le Duy Pham
HPHae-Sim Park
Hae-Sim Park
A variety of novel asthma treatments have been developed based on phenotypes, and the clinical trial results show promising responses. This review summarizes the current knowledge of biomarkers for the determination of asthma phenotypes. Eosinophilic inflammation is the most focused phenotype because most novel asthma treatments have targeted T-helper type 2 (Th2) pathway. Fractional-exhaled nitric oxide (FeNO) is a new method that represents an eosinophilic airway inflammation with a significant correlation with sputum eosinophilia and asthma severity instead of sputum eosinophil count that easily influenced by corticosteroid therapy. However, some reports indicated the discordance between treatment response or adjustment and FeNO levels. Serum periostin is a strong serum biomarker for eosinophilic airway inflammation and an indicator of Th2-targeted therapy (such as lebrikizumab or omalizumab) and airflow limitation. YKL-40 is associated with asthma severity and airway remodeling. In addition, genetic and metabolomic approaches have been made to determine asthma phenotypes and severity. Biomarkers such as FeNO and serum periostin represent eosinophilic airway inflammation, together with eosinophil-derived neurotoxin and osteopontin (OPN) needed more replication studies. Periostin, YKL-40, OPN and some metabolites (choline, arginine, acetone and protectin D1) are related to asthma severity and airflow limitation.

1 January 2015 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YSYooseob Shin
Yooseob Shin
DSDong-Hyeon Suh
Dong-Hyeon Suh
EYEun-Mi Yang
Eun-Mi Yang
YYYoung-Min Ye
Young-Min Ye
HPHae-Sim Park
Hae-Sim Park
Shin YS, et al. J Korean Med Sci. 2015 Jun;30(6):705-709. https://doi.org/10.3346/jkms.2015.30.6.705

17 July 2019 in Clinical and Translational Allergy
Verified
Journal Article
Open access
PDF file
BUBastsetseg Ulambayar
Bastsetseg Ulambayar
EYEun-Mi Yang
Eun-Mi Yang
HCHyun-Young Cha
Hyun-Young Cha
YSYooseob Shin
Yooseob Shin
HPHae-Sim Park
Hae-Sim Park
YYYoung-Min Ye
Young-Min Ye
Platelet activating factor (PAF) is an endogenous, active phospholipid released from inflammatory cells, platelets, and endothelial cells, and is involved in the regulation of immune responses. Degradation of PAF by PAF acetylhydrolase (PAF-AH) has been shown to be associated with anaphylaxis, asthma, and peanut allergy. The purpose of this study was to investigate relationships among clinical parameters, including urticaria severity and treatment responsiveness, and PAF and PAF-AH levels in sera from patients with chronic spontaneous urticaria (CSU). Serum PAF and PAF-AH levels were measured by enzyme-linked immunosorbent assay in 283 CSU patients and 111 age- and sex-matched, healthy normal controls (NCs). Urticaria severity was evaluated by urticaria activity score over 7 days (UAS7). Within 3 months after measuring PAF levels, patients whose urticaria was not controlled by antihistamine treatment were classified as histamine receptor 1 antagonist (H1RA) non-responders. Serum PAF levels were significantly higher in CSU patients than in NCs (median 4368.9 vs. 3256.4 pg/ml, p = 0.015), while serum PAF-AH levels were significantly lower in CSU patients (105.6 vs. 125.7 ng/ml, p = 0.001). H1RA non-responders had higher levels of PAF in their sera than H1RA responders. A generalized linear model revealed that a higher UAS7 score (odds ratio 1.023, p = 0.024) and a PAF level ≥ 5000 pg/ml (1.409, p < 0.001) were significant predictors of a poor response to H1RA treatment. Compared with NCs, CSU patients, particularly those with H1RA refractoriness, showed significant increases in serum PAF levels and decreases in PAF-AH. Therapies modulating PAF and PAF-AH levels could be effective in patients with CSU refractory to antihistamines.

1 January 2022 in Allergy, Asthma & Immunology Research
Verified
Journal Article
Open access
PDF file
TBTra Cao Thi Bich
Tra Cao Thi Bich
QQQuang Luu Quoc
Quang Luu Quoc
YCYoungwoo Choi
Youngwoo Choi
EYEun-Mi Yang
Eun-Mi Yang
TTTu HK Trinh
Tu HK Trinh
HPHae-Sim Park
Hae-Sim Park
Bich TC, et al. Allergy Asthma Immunol Res. 2022 Jan;14(1):40-58. https://doi.org/10.4168/aair.2022.14.1.40